Antiangiogenic Therapy for Cancer: Current and Emerging Concepts
作者： Rakesh K. Jain
DOI:
关键词: Cancer research 、 Drug delivery 、 Tumor angiogenesis 、 Cancer 、 Antiangiogenic therapy 、 Colorectal cancer 、 Tumor microenvironment 、 Medicine 、 Structure and function 、 Angiogenesis 、 Pharmacology
摘要: Angiogenesis is an essential step in the growth and spread of solid tumors-the cause more than 85% cancer mortality. Inhibiting angiogenesis would therefore seem to be a reasonable approach prevent or treat cancer. However, tumor differs from normal that resulting vessels are tortuous, irregularly shaped, hyperpermeable. These abnormalities result irregular blood flow high interstitial fluid pressure within tumor, which can impair delivery oxygen (a known radiation sensitizer) drugs tumor. Emerging evidence suggests antiangiogenic therapy prune some normalize structure function rest, thereby improving drug normalizing microenvironment. This normalization effect may underlie therapeutic benefit combined cytotoxic therapies. paper reviews current emerging concepts mechanism action therapies discusses implications these mechanisms for their optimal clinical use.
cancernetwork.com参考文章(75)
Peter Carmeliet, Mechanisms of angiogenesis and arteriogenesis. Nature Medicine. ,vol. 6, pp. 389- 395 ,(2000) , 10.1038/74651
Timothy P. Padera, Dai Fukumura, Ananth Kadambi, Peter Carmeliet, Dennis E. J. G. J. Dolmans, Rakesh K. Jain, Chae-ok Yun, Carla Mouta Carreira, Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A. Cancer Research. ,vol. 61, pp. 2404- 2408 ,(2001)
Napoleone Ferrara, Kenneth J Hillan, Hans-Peter Gerber, William Novotny, None, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nature Reviews Drug Discovery. ,vol. 3, pp. 391- 400 ,(2004) , 10.1038/NRD1381
Jeffrey M. Isner, Myocardial gene therapy Nature. ,vol. 415, pp. 234- 239 ,(2002) , 10.1038/415234A
Peter Carmeliet, Rakesh K. Jain, Angiogenesis in cancer and other diseases Nature. ,vol. 407, pp. 249- 257 ,(2000) , 10.1038/35025220
Rakesh K. Jain, Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nature Medicine. ,vol. 7, pp. 987- 989 ,(2001) , 10.1038/NM0901-987
Susan LeJeune, Russell Leek, Stephen Fox, Ruth Whitehouse, Amir Moghaddam, Prudence A. E. Scott, Roy Bicknell, Micheie Relf, Kenneth Smith, Adrian L. Harris, Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Research. ,vol. 57, pp. 963- 969 ,(1997)
Philippe Martinive, Bernard Gallez, Christine Baudelet, Pierre Sonveaux, Réginald Ansiaux, Nelson Beghein, Olivier Feron, Bénédicte F. Jordan, Vincent Grégoire, Julie De Wever, Thalidomide Radiosensitizes Tumors through Early Changes in the Tumor Microenvironment Clinical Cancer Research. ,vol. 11, pp. 743- 750 ,(2005)
B Coiffier, C Gisselbrecht, J M Vose, H Tilly, R Herbrecht, A Bosly, J O Armitage, Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. Journal of Clinical Oncology. ,vol. 9, pp. 211- 219 ,(1991) , 10.1200/JCO.1991.9.2.211
B Coiffier, C Gisselbrecht, R Herbrecht, H Tilly, A Bosly, N Brousse, LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. Journal of Clinical Oncology. ,vol. 7, pp. 1018- 1026 ,(1989) , 10.1200/JCO.1989.7.8.1018